New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
Search
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
Romy's Third-generation Japanese American Journey
Romy's Third-generation Japanese American Journey
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
Investigating MDM2-p53 in cancer
Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
US Privacy Statement
US Privacy Statement
She finds purpose in the saddle and pursues a passion for horses – at home and work
She finds purpose in the saddle and pursues a passion for horses – at home and work
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.
Sustainable cattle production: Feeding the world while minimizing environmental effect
Sustainable cattle production: Feeding the world while minimizing environmental effect
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Our Partners: University of Georgia USA
Our Partners: University of Georgia USA
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19